These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27491718)

  • 21. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
    Padovani RP; Robenshtok E; Brokhin M; Tuttle RM
    Thyroid; 2012 Aug; 22(8):778-83. PubMed ID: 22780333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance Evaluation of the Serum Thyroglobulin Assays With Immunochemiluminometric Assay and Immunoradiometric Assay for Differentiated Thyroid Cancer.
    Cho YY; Chun S; Lee SY; Chung JH; Park HD; Kim SW
    Ann Lab Med; 2016 Sep; 36(5):413-9. PubMed ID: 27374705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.
    Fugazzola L; Mihalich A; Persani L; Cerutti N; Reina M; Bonomi M; Ponti E; Mannavola D; Giammona E; Vannucchi G; di Blasio AM; Beck-Peccoz P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3201-8. PubMed ID: 12107225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
    Kloos RT; Mazzaferri EL
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5047-57. PubMed ID: 15972576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.
    Chindris AM; Diehl NN; Crook JE; Fatourechi V; Smallridge RC
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2714-23. PubMed ID: 22639286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
    Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
    Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.
    Spencer C; Petrovic I; Fatemi S
    J Clin Endocrinol Metab; 2011 May; 96(5):1283-91. PubMed ID: 21325460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer.
    Giovanella L; Ceriani L
    Clin Chem Lab Med; 2002 May; 40(5):480-4. PubMed ID: 12113292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the BRAHMS KRYPTOR thyroglobulin "mini-recovery" test in thyroid healthy subjects.
    Verburg FA; Grelle I; Giovanella L; Reiners C
    Horm Metab Res; 2012 Jun; 44(7):555-7. PubMed ID: 22689210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
    Pacini F; Lippi F
    J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
    Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
    Castagna MG; Brilli L; Pilli T; Montanaro A; Cipri C; Fioravanti C; Sestini F; Capezzone M; Pacini F
    J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the BRAHMS Kryptor(®) thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma.
    Giovanella L; Imperiali M; Verburg FA; Ceriani L
    Clin Chem Lab Med; 2013 Feb; 51(2):449-53. PubMed ID: 23095203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.